Fox Greg J, Nguyen Thu Anh, Coleman Mikaela, Trajman Anete, Velen Kavindhran, Marais Ben J
Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia; The Woolcock Institute of Medical Research, Glebe, NSW, 2006, Australia.
The Woolcock Institute of Medical Research, Hanoi, 10000, Viet Nam.
Int J Infect Dis. 2021 Dec;113 Suppl 1:S13-S15. doi: 10.1016/j.ijid.2021.02.094. Epub 2021 Mar 11.
Latent tuberculosis infection affects one quarter of the world's population, and effective therapies are available. However, scale-up of tuberculosis preventive treatment (TPT) remains limited. We describe strategies to support scale-up of TPT in high-prevalence settings, where the potential benefit for affected individuals is considerable. Patients must be at the centre of policies to scale-up TPT. Addressing the health system requirements for scale-up will ensure that programs can deliver treatment safely, efficiently and sustainably. Further research is required to adapt TPT to local contexts, and develop new shorter treatments that will be suitable for wide-scale deployment.
潜伏性结核感染影响着全球四分之一的人口，且有有效的治疗方法。然而，结核病预防性治疗（TPT）的推广仍然有限。我们描述了在高流行环境中支持TPT扩大规模的策略，在这些环境中，对受影响个体的潜在益处相当大。患者必须成为扩大TPT规模政策的核心。满足扩大规模的卫生系统要求将确保项目能够安全、高效和可持续地提供治疗。需要进一步开展研究，使TPT适应当地情况，并开发适合大规模推广的新的短疗程治疗方法。
